Auckland BioSciences Expands Into High-Value Nutraceuticals Sector With Acquisition Of Genesis BioLab

Auckland BioSciences adds further manufacturing capability of biological resources

AUCKLAND, New Zealand – Auckland BioSciences has acquired Genesis BioLab, a Christchurch-based specialist in high-end manufacturing for bioactives and neutraceuticals destined for the global health, nutrition, nutraceutical, pharmaceutical and research markets. The deal follows the opening of the company’s new business MonteSera in Uruguay in October.

Genesis BioLab adds more than 30 years of specialist expertise to Auckland BioSciences’ business operations, including capabilities in extraction, freeze-drying and bulk processing of nutraceutical products. Genesis BioLab has a strong track record across botanical, animal and marine-based ingredient extraction and manufacture, as well as the ability to take these ingredients from raw material directly through to finished consumer products in-house. The company is recognised for co-developing innovative products with customers and scaling them for export, and also for its longstanding supply relationships in the United States.

“This acquisition is about taking what Genesis BioLab does well and amplifying it on a global stage,” says Daniel Maxwell, Group General Manager. “We see enormous potential in combining their expertise with our international networks and proven ability to scale.”

Auckland BioSciences will integrate Genesis BioLab into its existing footprint across New Zealand, Australia and Uruguay. The company will use its global pharma and biotech network to manufacture and export high-grade wellness, pharmaceutical and nutraceutical ingredients, leveraging the technologies, systems and relationships that underpin its core serum and biologics operations. Genesis BioLab also enables Auckland BioSciences to refine a wider range of New Zealand-sourced biological materials.

“Our intention is to take Genesis BioLab’s products beyond the US and into Asia and Europe through our existing business networks, we’re targeting the world’s most valuable pharmaceutical, nutraceutical, and wellness markets,” says Maxwell.

The U.S. nutraceutical ingredient market is valued at more than US$160 billion and projected to grow to over US$230 billion by 2030, there is significant export opportunity for high-grade New Zealand-processed materials. More broadly, the U.S. wellness economy is estimated at about US$2 trillion, it’s the biggest wellness market in the world.

The acquisition is the continuation of Auckland BioSciences’ acquisition-based growth strategy. It broadens the company’s base pharmaceutical and biologics operations into adjacent categories where quality, traceability, and provenance carry strong commercial value.

“Our acquisition strategy is focused on expanding capability, growing export channels, and putting local ingenuity and the New Zealand brand to work globally – both organically and through targeted acquisitions. The Genesis BioLab purchase realises that strategy and demonstrates consistent achievement of the company’s growth expectations,” says Maxwell.

The Genesis BioLab acquisition follows a period of sustained expansion for Auckland BioSciences. The company recently announced the addition of CellSera (2021) in Australia and of MonteSera (2025) in Uruguay – where the President of Uruguay, Yamandú Orsí and The Hon. Andrew Hoggard, New Zealand Minister for Biosecurity were in attendance. The facility is collocated alongside Google and other large tech companies in the Parque de las Ciencias official free trade zone. The company has also featured in the Deloitte Fast 50 Index and won the NZTE Best Emerging Business award in 2018, was ranked #1 on the Deloitte Master of Growth Index in 2022, and was a finalist in NZTE’s International Business Awards for Best Large Business in 2023.

About Auckland BioSciences

Auckland BioSciences Ltd manufactures and exports premium New Zealand-made animal-derived serum and plasma. It produces animal sera and plasma in strictly controlled environments, using specialised facilities and equipment, to ensure scale and quality. Its sera are derived from New Zealand livestock classified as a safe and disease-free, due to the country’s stringent regulations. The company’s products are used for medical research and in the manufacture of therapeutic products such as vaccines. It exports to 20 countries and some of the world’s largest markets including the EU, the USA, Japan, Australia, Brazil, India and China. In 2021 and 2025 respectively, Auckland BioSciences acquired CellSera Australia, a New South Wales-based company and established MonteSera, a Uruguay based company, both specialising in the production of animal sera.

© Scoop Media